Wire · opportunities
University of Oxford spinout doses first patient in oesophageal cancer vaccine trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 August 2026 · Fusion42 review
Oxford spinout Infinitopes has dosed the first patient in a clinical trial of their ITOP1 vaccine, designed to enhance immune response against oesophageal and gastro-oesophageal junction adenocarcinoma. The VISTA trial will evaluate vaccine safety, immune response, and its potential to reduce cancer recurrence when administered before surgery.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to pivot quickly if your biotech works in cancer vaccines as Oxford’s spinout proves immune priming before surgery could reshape treatment timing and outcomes. Consider clinical collaborations now to stay ahead as this approach risks becoming a new standard with sizeable patient benefit.
◆ Coverage
1 source · 11 Aug 2026
◆ Related on Wire
◆ Topics